Table 2.
RETREAT score to estimate the risk of tumor recurrence after liver transplantation in patients with tumors within the Milan criteria and proposed protocol for tumor recurrence screening[74]
| Risk factor | Score |
| Alpha-fetoprotein level before LT | |
| 0–20 ng/mL | 0 |
| 21–99 ng/mL | 1 |
| 0–999 ng/mL | 2 |
| > 1000 ng/mL | 3 |
| Microvascular invasion | 2 |
| Sum of the diameter of the largest viable tumor and the number of viable nodules | |
| 0 | 0 |
| 1.1–4.9 | 1 |
| 5.0–9.9 | 2 |
| ≥ 10 | 3 |
| RETREAT Score | Screening Protocol |
| 0 points | Screening not needed |
| 1-3 points | Screening every 6/6 mo for 2 yr |
| 4 points | Screening every 6/6 mo for 5 yr |
| ≥5 points | Screening every 3-4 mo for 2 yr Exams every 6 mo between the 2nd and 5th year |
TR: Tumor recurrence; LT: Liver transplantation.